BACKGROUND:Type 2 diabetes mellitus (T2DM) is characterized by a proinflammatory and procoagulant condition. This study investigates the impact of a pioglitazone plus metformin therapy on biomarkers of inflammation and platelet activation in comparison to a treatment with glimepiride plus metformin. METHODS: The study was designed as a multicenter, randomized, double-blinded two-arm trial. Patients with T2DM and dyslipidemia under metformin monotherapy with hemoglobin A1c value between 6.5% and 9.0% were eligible for trial participation. Blood was drawn at baseline and after 24 weeks of treatment from patients of five centers. Markers of inflammation and thrombocyte function (soluble CD40 ligand, thromboxane, vWillebrand factor, adhesion molecules, clotting reaction) were evaluated subsequently in a central laboratory. RESULTS:A total of 46 patients were included in the final analyses. Mean (± standard deviation) age was 58.5 ± 9.0 years (13 women, 33 men; disease duration 6.3 ± 5.0 years; body mass index 32.0 ± 4.8 kg/m(2)). A total of 25 patients were treated with pioglitazone plus metformin, and 21 patients were in the glimepiride arm. There was a significant decline of E-selectin (-3.7 ± 4.8 ng/ml, p < .001 versus baseline), vWillebrand factor (-19.5 ± 32.0%, p < .05), and high-sensitivity C-reactive protein concentrations (-1.08 ± 0.91 mg/liter, p < .05) in the metformin + pioglitazone arm only (metformin + glimepiride, -0.5 ± 3.4 ng/ml, +1.4 ± 33.2%, + 0.08 ± 0.72 mg/liter, respectively, all not significant). Also, all other surrogate markers for platelet function and inflammation showed slight improvements in the metformin + pioglitazone arm but not in the metformin + glimepiride arm. CONCLUSIONS: The fixed metformin + pioglitazone combination treatment showed an overall improvement of laboratory surrogate markers, indicating improvement of platelet function and of chronic systemic inflammation, which was not seen with metformin + glimepiride.
RCT Entities:
BACKGROUND:Type 2 diabetes mellitus (T2DM) is characterized by a proinflammatory and procoagulant condition. This study investigates the impact of a pioglitazone plus metformin therapy on biomarkers of inflammation and platelet activation in comparison to a treatment with glimepiride plus metformin. METHODS: The study was designed as a multicenter, randomized, double-blinded two-arm trial. Patients with T2DM and dyslipidemia under metformin monotherapy with hemoglobin A1c value between 6.5% and 9.0% were eligible for trial participation. Blood was drawn at baseline and after 24 weeks of treatment from patients of five centers. Markers of inflammation and thrombocyte function (soluble CD40 ligand, thromboxane, vWillebrand factor, adhesion molecules, clotting reaction) were evaluated subsequently in a central laboratory. RESULTS: A total of 46 patients were included in the final analyses. Mean (± standard deviation) age was 58.5 ± 9.0 years (13 women, 33 men; disease duration 6.3 ± 5.0 years; body mass index 32.0 ± 4.8 kg/m(2)). A total of 25 patients were treated with pioglitazone plus metformin, and 21 patients were in the glimepiride arm. There was a significant decline of E-selectin (-3.7 ± 4.8 ng/ml, p < .001 versus baseline), vWillebrand factor (-19.5 ± 32.0%, p < .05), and high-sensitivity C-reactive protein concentrations (-1.08 ± 0.91 mg/liter, p < .05) in the metformin + pioglitazone arm only (metformin + glimepiride, -0.5 ± 3.4 ng/ml, +1.4 ± 33.2%, + 0.08 ± 0.72 mg/liter, respectively, all not significant). Also, all other surrogate markers for platelet function and inflammation showed slight improvements in the metformin + pioglitazone arm but not in the metformin + glimepiride arm. CONCLUSIONS: The fixed metformin + pioglitazone combination treatment showed an overall improvement of laboratory surrogate markers, indicating improvement of platelet function and of chronic systemic inflammation, which was not seen with metformin + glimepiride.
Authors: Stefania Basili; Giovanni Pacini; Maria Teresa Guagnano; Maria Rosaria Manigrasso; Francesca Santilli; Caterina Pettinella; Giovanni Ciabattoni; Carlo Patrono; Giovanni Davì Journal: J Am Coll Cardiol Date: 2006-11-28 Impact factor: 24.094
Authors: Irlando Andrade Ferreira; Astrid I M Mocking; Marion A H Feijge; Gertie Gorter; Timon W van Haeften; Johan W M Heemskerk; Jan-Willem N Akkerman Journal: Arterioscler Thromb Vasc Biol Date: 2005-12-08 Impact factor: 8.311
Authors: R Berria; L Glass; A Mahankali; Y Miyazaki; A Monroy; E De Filippis; K Cusi; E Cersosimo; R A Defronzo; A Gastaldelli Journal: Clin Pharmacol Ther Date: 2007-03-14 Impact factor: 6.875
Authors: T Forst; E Karagiannis; G Lübben; C Hohberg; T Schöndorf; G Dikta; M Drexler; M Morcos; W Dänschel; M Borchert; A Pfützner Journal: Atherosclerosis Date: 2007-06-22 Impact factor: 5.162
Authors: Alyssa L Thomas; Pablo C Alarcon; Senad Divanovic; Claire A Chougnet; David A Hildeman; Maria E Moreno-Fernandez Journal: Front Aging Date: 2021-09-22
Authors: Amanda Croasdell; Parker F Duffney; Nina Kim; Shannon H Lacy; Patricia J Sime; Richard P Phipps Journal: PPAR Res Date: 2015-12-02 Impact factor: 4.964
Authors: Luana Amorim Biondo; Edson Alves Lima Junior; Camila Oliveira Souza; Maysa Mariana Cruz; Roberta D C Cunha; Maria Isabel Alonso-Vale; Lila Missae Oyama; Claudia M Oller Nascimento; Gustavo Duarte Pimentel; Ronaldo V T Dos Santos; Fabio Santos Lira; José Cesar Rosa Neto Journal: PLoS One Date: 2016-03-25 Impact factor: 3.240
Authors: Katie L Lannan; Julie Sahler; Nina Kim; Sherry L Spinelli; Sanjay B Maggirwar; Olivier Garraud; Fabrice Cognasse; Neil Blumberg; Richard P Phipps Journal: Front Immunol Date: 2015-02-13 Impact factor: 7.561